Author | John M. Pagel, MD, PhD | OncLive

Author | John M. Pagel, MD, PhD

Articles

Dr. Pagel on the Implications of Polatuzumab Vedotin Approval in DLBCL

May 14, 2020

Video

John M. Pagel, MD, PhD, discusses the implications of the FDA approval of polatuzumab vedotin in diffuse large B-cell lymphoma.

Dr. Pagel on the Implications of Polatuzumab Vedotin Approval in DLBCL

May 13, 2020

Video

John M. Pagel, MD, PhD, discusses the implications of the FDA approval of polatuzumab vedotin in diffuse large B-cell lymphoma.

Dr. Pagel on the Shift Toward Precision Medicine in Large Cell Lymphoma

May 07, 2020

Video

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses the shift toward precision medicine in large cell lymphoma.

Dr. Pagel on Ongoing Research With BTK Inhibitors in CLL

May 06, 2020

Video

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

x